OptiBiotix Health PLC Director's Dealing (5123A)

TIDMOPTI

RNS Number : 5123A

OptiBiotix Health PLC

29 May 2019

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Director's Dealing

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification on 29 May 2019 that Frédéric Narbel, a recently appointed Director of the Company, acquired 12,000 ordinary shares in the Company on 29 May 2019, representing 0.01% of the Company's issued share capital, at a price of 89 pence per share.

Prior to this announcement, Mr Narbel did not hold any ordinary shares in the Company.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.

For further information, please contact:

 
 OptiBiotix Health plc                                                         www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                             Contact via Walbrook 
                                                                                            below 
 
 Cairn Financial Advisers LLP (NOMAD)                                          Tel: [phone] 
 Liam Murray / Jo Turner 
 
 finnCap (Broker)                                                              Tel: [phone] 
 Geoff Nash/ Scott Mathieson / Kate Bannatyne 
  (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                                  Tel: [phone] or [e-mail] 
 Anna Dunphy                                                                   Mob: [phone] 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty five international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
        ------------------------------------------------------------------------------------------ 
 a.      Name                                     Frédéric André Narbel 
        ---------------------------------------  ------------------------------------------------- 
 2       Reason for notification 
        ---------------------------------------  ------------------------------------------------- 
 a.      Position/Status                          Director of the Company 
        ---------------------------------------  ------------------------------------------------- 
 b.      Initial notification/                    Initial Notification 
          Amendment 
        ---------------------------------------  ------------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
        ------------------------------------------------------------------------------------------ 
 a.      Name                                     OptiBiotix Health Plc 
        ---------------------------------------  ------------------------------------------------- 
 b.      LEI                                      213800UKYQFT941QHS14 
        ---------------------------------------  ------------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
        ------------------------------------------------------------------------------------------ 
 a.      Description of                           12,000 ordinary shares of 2p each 
          the financial 
          instrument, type 
          of instrument                            ISIN: GB00BP0RTP38 
 
          Identification 
          Code 
        ---------------------------------------  ------------------------------------------------- 
 b.      Nature of the                            Purchase of 12,000 ordinary shares in the 
          transaction                              Company 
        ---------------------------------------  ------------------------------------------------- 
 
 c.      Price(s) and volume(s)                    Price(s) per               Volume(s) 
                                                    share 
        ---------------------------------------   ------------------------- 
                                                   89p                        12,000 
                                                  -------------------------  ----------------- 
 
 e.      Date of the transaction                  29 May 2019 
        ---------------------------------------  ------------------------------------------------- 
 f.      Place of the transaction                 London Stock Exchange, AIM 
        ---------------------------------------  ------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHZKLFLKEFFBBZ

(END) Dow Jones Newswires

May 29, 2019 10:17 ET (14:17 GMT)